who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Barbar Burger of Chevron, David Aaronson of REVs, and Andrea Young of DonateStock. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from energy to fintech — recently making headlines in Houston innovation.

Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures

The InnovationMap Awards will celebrate Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures, as this year's Trailblazer Award honoree. Photo courtesy of CTV

The inaugural Trailblazer Award at the 2021 InnovationMap Awards event was established to honor a Houston innovation leader and advocate who's making a lasting impact on the Houston innovation community. Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures, was selected to receive award.

"I am deeply honored to be recognized for my contributions to the Houston Innovation Ecosystem. I moved to Houston in 2013 and in short order was included and saw ways I could contribute. That is a great welcome! While I am proud of my contributions and our progress, we are just getting started," Burger says.

Burger leads Chevron's corporate venture arm, Chevron Technology Ventures, which has invested millions in the future of energy technology. This type of corporate venture activity — especially in a city with so many Fortune 500 companies — plays a key role in an innovation community. Click here to read more.

David Aaronson, founder of REVS

David Aaronson of REVS shares his EV entrepreneurial journey on the Houston Innovators Podcast. Photo courtesy of REVS

It might not be today, and it might not be tomorrow, but electric vehicles are coming into Texas at an increasing rate. EVolve Houston, founded in part by the city, predicts that EV sales locally will make up 30 percent of annual new car sales by 2030. Aaronson says they reported that Houston has around 15,000 EVs on the road today, but by 2030, that's going to be 600,000.

"If it's not 2030 it's going to be 2032, because it's all the manufacturers are making," David Aaronson, founder of REVS, says on this week's episode of the Houston Innovators Podcast. "It's just a matter of time."

Aaronson, a Houston real estate veteran, founded Refuel Electric Vehicle Solutions, or REVS, last year to become the go-between for multifamily property owners and managers and the charging technology providers. Click here to read more and stream the episode.

Andrea Young, co-founder and CEO of DonateStock

DonateStock, a Houston fintech company that simplifies the stock donation process, has officially launched. Image courtesy of DonateStock

A few years back, Andrea Young donated some of her stock, and the process, while having its perks, wasn't worth the trouble.

"I valued the immense benefits stock donations provided me as an investor while simultaneously helping a nonprofit," Young says of her early experience with donating stock. "I enjoyed the significant tax advantages that allowed me to avoid capital gains taxes while deducting the full market value of my gifted stock. However, I found the entire process time consuming and cumbersome, which led to the end of my stock donation journey."

When the pandemic hit and nonprofits were greatly impacted, Young and her co-founder saw an opportunity to found DonateStock to help drive donations and guide nonprofits and donors alike through the process. During its beta testing phase, the company partnered with almost 100 nonprofits. Click here to read more.

Trending News

Building Houston

 
 

From a low-cost vaccine to an app that can help reduce exposure, here are the latest COVID-focused and Houston-based research projects. Photo via Getty Images

While it might seem like the COVID-19 pandemic has settled down for the time being, there's plenty of innovative research ongoing to create solutions for affordable vaccines and tech-enabled protection against the spread of the virus.

Some of that research is happening right here in Houston. Here are two innovative projects in the works at local institutions.

UH researcher designs app to monitor best times to shop

A UH professor is putting safe shopping at your fingertips. Photo via UH.edu

When is the best time to run an errand in the pandemic era we currently reside? There might be an app for that. Albert Cheng, professor of computer science and electrical and computer engineering at the University of Houston, is working on a real-time COVID-19 infection risk assessment and mitigation system. He presented his plans at the Institute of Electrical and Electronics Engineers conference HPC for Urgent Decision Making and will publish the work in IEEE Xplore.

Cheng's work analyzes up-to-date data from multiple open sources to see when is the best time to avoid crowds and accomplish activities outside the home.

"Preliminary work has been performed to determine the usability of a number of COVID-19 data websites and other websites such as grocery stores and restaurants' popular times and traffic," Cheng says in a UH release. "Other data, such as vaccination rates and cultural factors (for example, the percentage of people willing to wear facial coverings or masks in an area), are also used to determine the best grocery store to shop in within a time frame."

To use the app, a user would input their intended destinations and the farthest distance willing to go, as well as the time frame of the trip. The risk assessment and mitigation system, or RT-CIRAM, then "provides as output the target location and the time interval to reach there that would reduce the chance of infections," said Cheng.

There's a lot to it, says Cheng, and the process is highly reliant on technology.

"We are leveraging urgent high-performance cloud computing, coupled with time-critical scheduling and routing techniques, along with our expertise in real-time embedded systems and cyber-physical systems, machine learning, medical devices, real-time knowledge/rule-based decision systems, formal verification, functional reactive systems, virtualization and intrusion detection," says Cheng.

2 Houston hospitals team up with immunotherapy company for new vaccine for Africa

The new vaccine will hopefully help mitigate spread of the disease in Sub-Saharan Africa. Photo via bcm.edu

Baylor College of Medicine and Texas Children's Hospital have teamed up with ImmunityBio Inc. — a clinical-stage immunotherapy company — under a licensing agreement to develop a safe, effective and affordable COVID-19 vaccine.

BCM has licensed out a recombinant protein COVID-19 vaccine candidate that was developed at the Texas Children's Hospital Center for Vaccine Development to ImmunityBio. According to the release, the company engaged in license negotiations with the BCM Ventures team, about the vaccine that could address the current pandemic needs in South Africa.

"We hope that our COVID-19 vaccine for global health might become an important step towards advancing vaccine development capacity in South Africa, and ultimately for all of Sub-Saharan Africa," says Dr. Peter Hotez, professor and dean of the National School of Tropical Medicine at Baylor and co-director of the Texas Children's Hospital Center for Vaccine Development.

ImmunityBio, which was founded in 2014 by Dr. Patrick Soon-Shiong, is working on innovative immunotherapies that address serious unmet needs in infectious diseases, according to a news release from BCM.

"There is a great need for second-generation vaccines, which are accessible, durable and offer broad protection against the emerging variants," says Soon-Shiong. "ImmunityBio has executed on a heterologous ("mix-and-match") strategy to develop a universal COVID-19 vaccine. To accomplish this, we have embarked upon large-scale good manufacturing practices and development of DNA (adenovirus), RNA (self-amplifying mRNA) and subunit protein (yeast) vaccine platforms. This comprehensive approach will leverage our expertise in these platforms for both infectious disease and cancer therapies."

Trending News